Cosart — Research Summary
Cosart 50 mg Cipla is a pharmaceutical preparation containing losartan potassium, an angiotensin receptor blocker (ARB) manufactured by Cipla Pharmaceuticals. This compound represents the potassium salt form of losartan, extensively studied in cardiovascular research for its selective angiotensin II type 1 (AT1) receptor antagonist properties. Losartan research investigations examine its mechanism of blocking the renin-angiotensin-aldosterone system, which plays a crucial role in blood pressure regulation and cardiovascular pathophysiology. Research teams at Stroid UK Shop can evaluate this compound alongside other cardiovascular modulators for comprehensive laboratory studies.
Research Applications in Laboratory Settings
Research scientists investigate Cosart tablets in various experimental protocols examining cardiovascular function and angiotensin receptor signalling pathways. Laboratory studies analyse losartan’s competitive inhibition of angiotensin II binding to AT1 receptors in vascular smooth muscle and adrenal tissues. Researchers examine the compound’s effects on aldosterone secretion, vasoconstriction mechanisms, and cellular signalling cascades in controlled experimental environments. Comparative studies often evaluate this compound against other ARB compounds available in our losartan research category. Advanced research protocols investigate the active metabolite E-3174 formation through cytochrome P450 metabolism, which demonstrates enhanced potency and longer half-life characteristics. Studies examine dose-response relationships, receptor binding kinetics, and tissue-specific effects across multiple organ systems.
Technical Specifications
| Active Compound | Losartan Potassium |
|---|---|
| Strength | 50 mg per tablet |
| Manufacturer | Cipla Pharmaceuticals |
| Molecular Formula | C₂₂H₂₂ClKN₆O |
| Molecular Weight | 461.00 g/mol |
| CAS Number | 124750-99-8 |
| Storage Conditions | Room temperature, dry environment |
| Stability | 3 years from manufacture date |
This pharmaceutical preparation maintains consistent quality standards suitable for research applications requiring reliable compound integrity. Researchers can coordinate studies with complementary compounds from our SARMs collection and peptides range for comprehensive experimental protocols.
Research Compliance and Laboratory Use
This product is manufactured for in-vitro research applications only and is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must follow appropriate laboratory safety protocols and institutional guidelines when handling this compound. All studies should be conducted by qualified personnel in properly equipped laboratory facilities with adequate ventilation and safety measures in place.
